Trial Pause:: Intellia has paused dosing and screening in its MAGNITUDE and MAGNITUDE-2 trials after a patient experienced Grade 4 liver transaminase elevations and increased total bilirubin.
Patient Safety:: The patient, dosed on September 30, 2025, was hospitalized and is receiving medical intervention. Intellia is consulting with experts and regulatory authorities to develop a strategy to resume enrollment.
Enrollment Numbers:: Over 650 patients with ATTR-CM are enrolled in MAGNITUDE, and 47 patients with ATTR-PN are enrolled in MAGNITUDE-2. An estimated 450+ patients have been dosed with nex-z.
Nex-z Potential:: Nex-z is a CRISPR-based therapy with the potential to be the first one-time treatment for ATTR amyloidosis. It has received Orphan Drug and RMAT Designation from the FDA and Orphan Drug Designation from the European Commission.
Why this matters: Patient safety is paramount in clinical trials. This pause allows Intellia to investigate the adverse event, refine protocols, and ensure the well-being of participants before continuing the trials.
Intellia Therapeutics' decision to pause its Phase 3 trials highlights the inherent risks in gene-editing therapies. Liver damage has been a known concern for CRISPR-based medicines. The company's prompt action to halt the trials and investigate the event demonstrates a commitment to patient safety and regulatory compliance.
The MAGNITUDE trials are investigating nex-z, a CRISPR/Cas9 gene editing therapy designed to inactivate the TTR gene responsible for transthyretin amyloidosis. This condition leads to the buildup of abnormal protein deposits in various organs and tissues, causing significant health problems.
Background Context:: CRISPR/Cas9 technology offers the potential for one-time treatments by directly modifying genes. However, off-target effects and immune responses remain key challenges.
Data-Driven Insights:: The fact that over 450 patients have already been dosed with nex-z suggests a substantial amount of safety data is available, which will be crucial in determining the cause of the adverse event.
Actionable Takeaways:
Monitor Intellia's updates on the investigation and the timeline for resuming the trials.
Be aware of the potential risks associated with gene-editing therapies and the importance of rigorous safety monitoring.
Q: Why did Intellia pause the MAGNITUDE trials?
Intellia paused the trials due to a patient experiencing Grade 4 liver transaminase elevations and increased total bilirubin.
Q: What is nex-z?
Nex-z is a CRISPR-based gene editing therapy being investigated for the treatment of transthyretin amyloidosis (ATTR).
Q: How many patients are affected?
Over 650 patients are enrolled in the MAGNITUDE trial and 47 in MAGNITUDE-2. More than 450 patients have been dosed with nex-z.
- Intellia Therapeutics has paused its Phase 3 trials for nex-z due to a serious adverse event.
- The company is investigating the event and working with regulatory authorities.
- Patient safety remains the top priority.
- CRISPR-based therapies hold promise but also carry risks that require careful monitoring.
Do you think this pause will significantly delay the development of nex-z? Share your thoughts in the comments below!
Share this article with others who need to stay ahead of this trend!
Lyra Therapeutics (LYRA) has announced positive results from its ENLIGHTEN 2 Phase 3 clinical trial for LYR-210, a long-acting sinonasal imp...
Spero Therapeutics and GSK have announced positive results from their Phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigational or...
⚠ Disclaimer: Yanuki provides article summaries and links for reference only. Yanuki does not endorse, verify, or guarantee the accuracy of third-party sources. Please review original sources and verify information independently. Managed by the Yanuki Data Engine. Full Disclaimer